Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) traded up 8.8% on Wednesday . The stock traded as high as $39.74 and last traded at $38.84, with a volume of 1,202,474 shares changing hands. The stock had previously closed at $35.69.

Several equities research analysts have weighed in on the stock. Wedbush reissued an “outperform” rating and set a $113.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 20th. Mizuho assumed coverage on shares of Pacira Pharmaceuticals in a research report on Tuesday, April 19th. They set a “buy” rating and a $79.00 price target for the company. Canaccord Genuity reissued a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 20th. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. Finally, TheStreet lowered shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $78.15.

The stock’s market capitalization is $1.40 billion. The company has a 50-day moving average price of $39.36 and a 200 day moving average price of $51.92.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Monday, May 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.08. During the same period last year, the business earned $0.27 earnings per share. The company earned $65.50 million during the quarter, compared to analyst estimates of $67.11 million. The firm’s revenue was up 12.3% compared to the same quarter last year. Analysts predict that Pacira Pharmaceuticals Inc. will post $0.33 EPS for the current fiscal year.

In related news, Director Mark A. Kronenfeld sold 900 shares of the firm’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $46.95, for a total transaction of $42,255.00. Following the completion of the sale, the director now directly owns 2,950 shares of the company’s stock, valued at approximately $138,502.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Lauren Bullaro Riker sold 938 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $47.66, for a total value of $44,705.08. Following the sale, the vice president now directly owns 5,945 shares of the company’s stock, valued at $283,338.70. The disclosure for this sale can be found here.

Several hedge funds have modified their holdings of the company. Mutual of America Capital Management LLC increased its stake in shares of Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock worth $1,858,000 after buying an additional 142 shares during the last quarter. Stephens Inc. AR boosted its position in shares of Pacira Pharmaceuticals by 3.9% in the fourth quarter. Stephens Inc. AR now owns 21,557 shares of the company’s stock worth $1,655,000 after buying an additional 806 shares during the period. TD Asset Management Inc. boosted its position in shares of Pacira Pharmaceuticals by 1.8% in the fourth quarter. TD Asset Management Inc. now owns 74,700 shares of the company’s stock worth $5,736,000 after buying an additional 1,300 shares during the period. Rhumbline Advisers boosted its position in shares of Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock worth $3,261,000 after buying an additional 3,160 shares during the period. Finally, ProShare Advisors LLC boosted its position in shares of Pacira Pharmaceuticals by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 36,239 shares of the company’s stock worth $2,783,000 after buying an additional 3,477 shares during the period.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.